Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma (MM) is an incurable plasma cell cancer selectively localized in the bone marrow (BM). The main cause of resistance in myeloma is the minimal residual disease (MRD) cells that are resistant to the original therapy including bortezomib treatment and high dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in MM cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in MM; and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain of function studies using LDHA or HIF1A induced resistance in bortezomib sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in MM, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.
ABSTRACT
Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma (MM) is an incurable plasma cell cancer selectively localized in the bone marrow (BM). The main cause of resistance in myeloma is the minimal residual disease (MRD) cells that are resistant to the original therapy including bortezomib treatment and high dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in MM cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in MM; and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain of function studies using LDHA or HIF1A induced resistance in bortezomib sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in MM, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance. 
INTRODUCTION
Cellular metabolic versatility is essential for the maintenance of energy production throughout a range of oxygen concentrations (1) . Metabolic changes occurring in cancer cells are considered to be fundamental for the transformation of normal cells into cancer cells. A common property of invasive cancers is an altered glucose metabolism or glycolysis (1) . Glycolysis converts glucose into pyruvate and in normal cells; this process is inhibited by the presence of oxygen, which allows mitochondria to oxidize pyruvate to CO 2 and H 2 O. This inhibition is termed as the "Pasteur effect" (2) .
Conversion of glucose to lactic acid in the presence of oxygen is known as aerobic glycolysis or the "Warburg effect" and the increase of aerobic glycolysis is often observed in tumor cells (3) (4) (5) .
One of the most recognized reasons for altered tumor metabolism is hypoxia in the tumor microenvironment (6, 7) . Cells respond to the hypoxic microenvironment with the activation of hypoxia-inducible factor 1 (HIF1) transcription factor. The net result of hypoxic HIF1 activation is to shift energy production by increasing glycolysis and decreasing mitochondrial function (6) . The largest functional group of genes consistently regulated by HIF1 is associated with glucose metabolism. HIF1 increases the expression of the glucose transporters, enzymatic breakdown of glucose into pyruvate and enzymes involved in the pyruvate metabolism as well as lactate production (8, 9) . Although HIF1 was initially identified because of its response to low O 2 concentrations, it is now apparent that HIF1 can be regulated by other factors such as oncogene activation (RAS, MYC and PI3K) or loss of tumor suppressors including VHL (von Hippel-Lindau) or PTEN leading to increased glycolysis, angiogenesis and drug resistance (10) (11) (12) .
Research.
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Author Manuscript Published OnlineFirst on March 13, 2015 ; DOI: 10.1158/0008-5472.CAN- Multiple myeloma (MM) is an incurable plasma cell cancer selectively localized in the bone marrow (BM). The introduction of novel agents, including bortezomib in combination with autologous stem cell transplantation, has led to a significant advancement in the treatment of patients leading to complete response in many patients.
Unfortunately, most patients ultimately relapse due to the presence of surviving tumor cells at the minimal residual disease (MRD) state, suggesting the presence of drug resistance within specific niches in the BM. The BM has heterogeneous areas of hypoxia and these specific niches are altered during chemotherapy and radiation therapy (1) . We hypothesize that hypoxia in specific bone marrow niches regulates the maintenance of minimal residual disease cells which are resistant to treatment and have the capability to induce relapse. We sought to investigate the mechanism underlying this drug resistance through the cellular metabolic profile of MM cells in normoxic and hypoxic conditions. Our results reveal unprecedented features of MM cells metabolism and further demonstrate that LDHA and HIF1A are valid targets to prevent MM drug resistance and progression in vivo.
Research. performed using the "Comparative Marker Selection" tool to find the genes that are most closely correlated with the two phenotypes normoxia and hypoxia.
To determine the Gene enrichments sets of hypoxia-related pathways, glucose metabolism and TCA cycle in plasma cells isolated from normal subjects or from newly diagnosed MM patients, as well as from responder and relapsed patients to bortezomib, we used published datasets from the Gene Expression Omnibus by Chng W.J. et al and Mulligan G. et al (series numbers GSE6477 and GSE9782, respectively)) (16, 17) .
Metabolite profiling
Metabolites were extracted in ice-cold methanol and endogenous metabolite profiles were obtained using two liquid chromatography-tandem mass spectrometry (LC-MS) methods as described (18) . Data were acquired using a 5500 QTRAP triple quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC system (Shimadzu) via
Research. Metaboanalyst software was used for analysis. Metabolite levels were normalized to the total of all metabolites detected on a triplicate set of cells treated identically to the experimental cells.
Hexokinase activity and lactate measurement
Hexokinase activity was measured with the Hexokinase Assay Kit (Abcam) and cellular lactate levels were measured using the Lactate Colorimetric Assay Kit (Biovision) according to the manufacturer's instructions.
RNA purification, reverse transcription and quantitative RT-PCR (qRT-PCR)
Total RNA was prepared with QIAzol reagent (Invitrogen) according to the manufacturer's instructions. 1 µg of total RNA were reverse-transcribed using Hypoxyprobe Store). After 4 hours, BM was isolated from one femur by flushing with cold PBS and prepared for RNA isolation as described; the other femur was used for immunohistochemistry (IHC).
In vivo tumor growth has been assessed by using in vivo bioluminescence imaging. Mice were injected with 75 mg/kg of Luciferin (Xenogen, Hopkington, MA), and tumor growth was detected by bioluminescence 3 min after the injection, using 
Immunohistochemistry
In the in vivo model, femurs were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) in accordance with standard procedures. Immunohistochemistry was performed using antibodies against Mab1 (Hypoxyprobe Store), HK2 (Cell signaling) and LDHA (Cell signaling) according to manufacturer´s instructions. All MM biopsies were evaluated at DFCI, and the histological diagnosis was based on H&E. Histologic IHC images were obtained with the Olimpus AH2 Microscope Camera from Center Valley, PA. Image acquisition and processing software were performed using an Olimpus DP12 camera and software.
Knockdown constructs
Stable knockdowns of HIF1A, HIF2A, HK2 and LDHA were generated by lentiviral 
RESULTS
Hypoxia promotes drug resistance in multiple myeloma.
Research. We first examined hypoxia regulated pathways in primary MM patients to test the enrichment of HIF1A and HIF2A (15) pathways in plasma cells isolated from BM of normal donors and MM patients; we analyzed the published gene-expression datasets (series numbers, GSE6477 and GSE9782, respectively) (16, 17) . Newly diagnosed MM patients showed an enrichment of HIF1A and HIF2A pathways compared with normal donors (Supplemental Figure 1A) , we also found an enrichment of both pathways in patients with relapsed and bortezomib-refractory myeloma compared with patients responding to bortezomib (Supplemental Figure 1B) .
We next investigated whether hypoxia plays a role in drug resistance in MM. Figure 1D ) and H929 (Supplemental Figure 1E) cells. As hypoxia has been shown to cause cell cycle arrest and this could potentially impact therapeutic responses, we analyzed the effect of hypoxia on cell cycle regulation and apoptosis by flow cytometry. After 24 hours, hypoxia induced G1 arrest (Supplemental Figure 1F) but not apoptosis (Supplemental Figure 1G ) in MM cells.
However, induction of G1 arrest through serum starvation (Supplemental Figure 1H) did not impact the response to bortezomib in MM1S, RPMI8226 and H929 (Supplemental Figure 1I ). Carfilzomib showed similar activity to bortezomib on MM1S, RPMI8226 and H929 cells (Supplemental Figure 1J) . Therefore, the drug resistance effect observed with hypoxia was not due to the G1 arrest observed in hypoxic conditions. To further confirm the effect of hypoxia, we pretreated the cells for To determine specific metabolic changes are due to hypoxia and not to the G1 cell cycle arrest observed in hypoxic cells, we starved MM1S cells for 12 hours and the metabolic profile of MM1S cells arrested at G1 phase showed a decrease on glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate, pyruvate and lactate metabolites ( Figure 1C ). In contrast to G1 arrested cells, hypoxic cells showed an increase in glycolysis metabolites including pyruvate and lactate ( Figures 1C and 1D ).
To further examine metabolic alterations in hypoxic conditions, we performed GEP on MM1S under normoxic or hypoxic conditions and performed GSEA using the ranked HIF1A is the main pathway to induce glycolysis and lactate production during hypoxia (20,22,23). Under low oxygen conditions, HIF1A is stabilized and promotes transcription of several genes critical for the cellular response to hypoxia (10) . We hypothesized that cells lacking HIF1A will fail to upregulate glycolytic enzymes and lactate production in response to hypoxia and will render them more sensitive to chemotherapy. To test this hypothesis, we performed HIF1A and HIF2A-loss of function studies in MM cells. HIF1A and HIF2A knockdown efficiencies were evaluated using qRT-PCR and western blot (Supplemental Figures 3A-C Figure   3A ). In MM1S-HIF2A knockdown, intermediates of glycolysis were slightly reduced, but pyruvate and lactate levels increased after hypoxia exposure ( Figure 3A) . The levels of TCA cycle intermediates decreased in HIF1A and HIF2A knockdowns compared with MM1S-scramble after either normoxia or hypoxia exposures ( Figure 3B ).
To confirm that the HIF1A and HIF2A knockdown metabolites patterns reflected a shift in glycolysis and mainly in lactate production, we measure hexokinase activity and lactate production in both cells under normoxic and hypoxic conditions. As expected, HIF1A knockdown cells showed a reduction in hexokinase activity under hypoxic conditions similar to normoxic levels ( Figure 3C ) and a significant decrease in lactate production in both normoxic and hypoxic levels compared with the scramble ( Figure 3D ). Hexokinase and lactate activities did not change in HIF2A knockdown cells ( Figures 3C and 3D ).
Research. Consistent with the metabolite profile pattern and the reduction of hexokinase and lactate levels, the HIF1A knockdown partially overcomes drug resistance to bortezomib ( Figure 3E ) and melphalan (Supplemental Figure 3D ) after hypoxia exposure. However, HIF2A knockdown did not produce similar results indicating that HIF2A is not essential for the induced drug resistance ( Figure 3F ).
To determine the in vivo effect of HIF1A loss, we knockdown HIF1A expression in MM1S-GFP/luc. HIF1A knockdown efficiency was evaluated by qRT-PCR (Supplemental Figure 3E ). MM1S-GFP/luc-scramble (n=14) and MM1S-GFP/lucshHIF1A (HIF1A knockdown) (clone 2) (n=14) were injected intravenously into NOD-SCID mice. After 10 days we started the treatment of each group (n=7 per group), 28 mice were treated with vehicle (n=14) or bortezomib (0.75 mg/Kg, weekly, intraperitoneal) (n=14). Tumor growth was measured using luciferin and bioluminescence (BLI).
After 35 days, the scramble group demonstrated significant tumor progression; whereas minimal tumor growth was detected in mice injected with HIF1A knockdown ( Figure 3G ). Mice groups injected with scramble cells and treated with bortezomib showed a delay in tumor growth, but after 35 days the tumor growth increased reaching similar BLI signal to the control group ( Figure 3G ). Bortezomib showed a significant effect in the HIF1A knockdown group (Figure 3G ), increasing the survival significantly compared with the non-treated group and compared with the control group treated with bortezomib ( Figure 3H ). Furthermore, mice femurs were collected at day 10 and at day 35; and CD138 expression was analyzed by IHC. In concordance with our BLI data, we observed an increase of CD138+ population with a strong staining in the scramble biopsies whereas the HIF1A knockdown group remained very low even at day 35 Similarly, GEP of an independent set of CD138+ cells (16, 17) , revealed that the expression of HK2 and LDHA increased with disease progression (Supplemental Figure   4C ).
We evaluated the effect of LDHA and HK2 knockdown on hexokinase activity and intracellular levels of lactate and found that knockdown of HK2 leads to inhibition of both hexokinase activity and lactate ( Figure 4D ), however LDHA knockdown showed a reduction in lactate but did not affect the cellular hexokinase activity compared with scramble control cells ( Figure 4E ).
We next examined the effect of bortezomib in HK2 and LDHA knockdowns. 
exposure to hypoxia ( Figure 4F ) whereas the effect of bortezomib was markedly higher in MM1S-shLDHA (LDHA knockdown) under both normoxic and hypoxic conditions ( Figure 4G ). We also examined the effect in response to melphalan treatment, and LDHA KD restored the effect of melphalan under hypoxic conditions (Supplemental Figure 4D) . Therefore, this effect shows that metabolism-induced drug resistance represents a common mechanism of resistance to drug therapy and not just specific to bortezomib or proteasome inhibition.
LDHA expression as well as pyruvate dehydrogenase kinase 1(PDK1) were found to be upregulated in the GEP data analysis. Both of these enzymes can limit the use of pyruvate as a carbon source for the TCA cycle (24,25). Indeed, our metabolomics data shows an overall decrease in TCA pool sizes under hypoxic conditions. To determine if pyruvate utilization plays a role in drug resistance, we performed gain of function experiments with PDK1 (Supplemental Figure 4E ) and examined the effect of bortezomib in PDK1 expressing cells under normoxic conditions. We observed that MM1S-PDK1 expressing cells were resistant to the effect of bortezomib (Supplemental 
showed a significant delay in tumor growth ( Figure 4H ). Survival curves showed a significant difference between the scramble and LDHA knockdown groups and bortezomib highly increased the survival percentage of the LDHA knockdown mice compared with the non-treated group and with the scramble treated group ( Figure 4I ).
The observed changes may be due to an impact of HIF1A-and LDHA-silencing on both bone marrow homing/engraftment of MM cells; together with a reduced MM cell growth. These data are indeed supported by the IHC studies where a reduced human-CD138 cell infiltration was documented in those mice that were injected with HIF1A-and LDHA-silenced MM1S cells compared to the related scramble control.
Mice femurs were collected at day 10 and IHC was performed to detect PIMO, HK2 and LDHA levels. In concordance with our in vitro data, even under hypoxic conditions as demonstrated by PIMO staining, LDHA knockdown group showed a lower HK2 expression in plasma cells ( Figure 4J ).
HIF1A and LDHA expression are associated with drug resistance.
To further confirm the dependence between HIF1A, LDHA and drug resistance, we examined the relative levels of HIF1A and LDHA in a panel of six MM representative cell lines: MM1S and MM1R (sensitive and resistant to dexamethasone), U266 and U266LR7 (sensitive and resistant to melphalan) and ANBL6 and ANBL6-bortezomib-resistant (BR) (sensitive and resistant to bortezomib, respectively).
We found that HIF1A ( Figure 5A ) and particularly LDHA ( Figure 5B It is well established that hypoxia and consequently HIF1A activation is associated with metastasis in solid tumors and with poor patients outcome (26-28), but the metabolic-induced phenotype driven to drug resistance has been poorly explored mainly because the lack of understanding of cellular responses to inhibition of specific enzymes involved in energy metabolism. In this study we demonstrate that altered metabolism has important implications for tumor cell growth and drug resistance. In this study, we demonstrate that the increase of glycolytic metabolism results in increased lactate levels in MM cells. Importantly, we show that increased glycolysis is not a consequence of the G1 arrest that cells undergo after hypoxia conditions. Rather, hypoxia actively regulates cellular glucose metabolism by activation of glycolytic enzymes transcription as we demonstrate by GEP analysis and at the functional level by enzymatic assays. Thus, taken together, our study shows that increased glycolysis leads to chemotherapy resistance in MM cells.
The role of dysregulated metabolism in therapeutic resistance has not been examined previously (12, (29) (30) (31) (32) (33) (34) . The ability to reduce chemoresistance through the inhibition of metabolic pathways would be an important research area to improve patient response to therapy. As a central energetic resource for the cell, glucose metabolism is quite complex. Many enzymes contribute to the glycolytic breakdown of glucose. In the glycolytic pathway, the first rate-limiting step is the transport of glucose across the plasma membrane through glucose transporters (GLUT family). GLUT family of proteins are often found upregulated in malignant cells (35). GLUT1 inhibitors, such us WZB117 and phloretin, decrease glucose uptake and display synergistic anticancer effects in lung, colon and breast cancer as well as in leukemia in vitro (36,37). Under hypoxia, the GLUT1 inhibitor, phloretin, significantly enhances daunorubicin effect and overcomes hypoxia-conferred drug resistance (38). Another key rate-limiting enzyme in glycolysis is HK, which has important roles in both glycolysis and apoptosis, and inhibitors of HK, such us 2-deoxyglucose (2-DG), 3-bromopyruvate Stable depletion of HIF1A inhibited glycolysis and decreased lactate levels and this reduction of lactate remained at low levels even after the exposure to hypoxia.
Reduction of HK2 and LDHA expression also increased the effect the bortezomib under hypoxic conditions, however due to the LDHA reduction observed in our stable HK2 knockdown and due to the fact that hexokinase activity was also decreased in cells treated with bortezomib under hypoxic conditions; we proposed that LDHA could be one of the main targets to overcome drug resistance induced through hypoxia. Depletion 
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Research. Histopathology was performed on different groups 10 days after injection. PIMO, HK2
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